Search results for "From Gastroenterology Monthly"

GLP-1s associated with increased risk of GERD

Patients with type 2 diabetes who started a glucagon-like peptide-1 (GLP-1) receptor agonist had a 27% higher risk of gastroesophageal reflux disease (GERD) than those who took a sodium-glucose cotransporter-2 inhibitor, a retrospective study found.
https://diabetes.acponline.org/archives/2025/08/08/9.htm
8 Aug 2025